Blood pressure in chronic kidney disease stage 5D—report from a Kidney Disease: Improving Global Outcomes controversies conference
Nathan W. Levin(Renal Research Institute), Gérard M. London(Unknown), Peter Kotanko(Renal Research Institute), Carmine Zoccali(Biogem), Josep Redón, Kai‐Uwe Eckardt(Friedrich-Alexander-Universität Erlangen-Nürnberg), David C. Wheeler(University College London), Bertram L. Kasiske(University of Minnesota), Alfred K. Cheung(University of Utah), Charles Chazot(Clinique Charcot)
Cited by 194
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
2018 ESC/ESH Guidelines for the management of arterial hypertension
|European Heart Journal|2018|10.5k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k